D Podzamczer

Summary

Affiliation: Hospital Universitari de Bellvitge
Country: Spain

Publications

  1. ncbi Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study Group
    D Podzamczer
    Infectious Disease Service, Ciutat Sanitaria de Bellvitge, c Feixa Llarga s n L Hospitalet, Barcelona, Spain
    Eur J Clin Microbiol Infect Dis 19:89-95. 2000
  2. ncbi A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study)
    Daniel Podzamczer
    Infectious Disease Service, Ciutat Sanitaria de Bellvitge, L Hospitalet, Barcelona, Spain
    Antivir Ther 7:81-90. 2002
  3. ncbi Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain
    J Acquir Immune Defic Syndr 44:139-47. 2007
  4. ncbi The role of nevirapine in the treatment of HIV-1 disease
    D Podzamczer
    Infectious Disease Service, Ciutat Sanitaria de Bellvitge, Barcelona, Spain
    Expert Opin Pharmacother 2:2065-78. 2001
  5. doi Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients
    Daniel Podzamczer
    Hospital Universitari de Bellvitge, L Hospitalet, Barcelona, Spain
    J Acquir Immune Defic Syndr 50:390-6. 2009
  6. ncbi Early virological failure with a combination of tenofovir, didanosine and efavirenz
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain
    Antivir Ther 10:171-7. 2005
  7. doi How much fat loss is needed for lipoatrophy to become clinically evident?
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Bellvitge, c Feixa Llarga s n L Hospitalet, Barcelona 08907, Spain
    AIDS Res Hum Retroviruses 25:563-7. 2009
  8. ncbi Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine
    Elena Ferrer
    Infectious Disease Service, Hospital Universitario de Bellvitge, Barcelona, Spain
    J Infect Dis 187:687-90. 2003
  9. ncbi High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain
    HIV Clin Trials 8:193-204. 2007
  10. doi Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clínic Institut d Investigaciones Biomèdiques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    AIDS 24:1697-707. 2010

Detail Information

Publications64

  1. ncbi Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study Group
    D Podzamczer
    Infectious Disease Service, Ciutat Sanitaria de Bellvitge, c Feixa Llarga s n L Hospitalet, Barcelona, Spain
    Eur J Clin Microbiol Infect Dis 19:89-95. 2000
    ..Administration of antiretroviral therapy was the only factor associated with a lower incidence of relapse...
  2. ncbi A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study)
    Daniel Podzamczer
    Infectious Disease Service, Ciutat Sanitaria de Bellvitge, L Hospitalet, Barcelona, Spain
    Antivir Ther 7:81-90. 2002
    ....
  3. ncbi Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain
    J Acquir Immune Defic Syndr 44:139-47. 2007
    ..To assess lipoatrophy, other toxicities, and efficacy associated with abacavir as compared with stavudine in HIV-infected antiretroviral-naive patients...
  4. ncbi The role of nevirapine in the treatment of HIV-1 disease
    D Podzamczer
    Infectious Disease Service, Ciutat Sanitaria de Bellvitge, Barcelona, Spain
    Expert Opin Pharmacother 2:2065-78. 2001
    ..Hepatotoxicity may also appear with nevirapine, mainly in patients with chronic hepatitis C and/or altered liver function tests. This side effect may occasionally be life-threatening but it can be safely managed in most patients...
  5. doi Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients
    Daniel Podzamczer
    Hospital Universitari de Bellvitge, L Hospitalet, Barcelona, Spain
    J Acquir Immune Defic Syndr 50:390-6. 2009
    ..The strategy of switching nevirapine (NVP) twice daily to once daily was evaluated...
  6. ncbi Early virological failure with a combination of tenofovir, didanosine and efavirenz
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain
    Antivir Ther 10:171-7. 2005
    ..To describe the occurrence of a high early virological failure (VF) rate and development of resistance mutations in antiretroviral-naive patients receiving tenofovir, didanosine and efavirenz...
  7. doi How much fat loss is needed for lipoatrophy to become clinically evident?
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Bellvitge, c Feixa Llarga s n L Hospitalet, Barcelona 08907, Spain
    AIDS Res Hum Retroviruses 25:563-7. 2009
    ..5 kg (sensitivity, 77%; specificity, 76%) and -30% (sensitivity, 85%; specificity, 73%). At least 30% limb fat is needed to be lost in HIV-infected patients for lipoatrophy to become clinically evident...
  8. ncbi Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine
    Elena Ferrer
    Infectious Disease Service, Hospital Universitario de Bellvitge, Barcelona, Spain
    J Infect Dis 187:687-90. 2003
    ..At failure, mutations were detected in 7 of 16 patients. An agreement in the results of virtual and real phenotypes was observed in the 93 samples in which both tests were performed...
  9. ncbi High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain
    HIV Clin Trials 8:193-204. 2007
    ..To investigate the efficacy and safety of high-dose lopinavir/ritonavir (LPV/r) therapy in multiple protease inhibitor, non-nucleoside reverse transcriptase inhibitor (NNRTI)-experienced subjects...
  10. doi Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clínic Institut d Investigaciones Biomèdiques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    AIDS 24:1697-707. 2010
    ..Switching to raltegravir in selected patients treated with ritonavir-boosted protease inhibitors may result in similar efficacy and lower plasma lipids...
  11. ncbi Health-related quality of life in HIV-infected naive patients treated with nelfinavir or nevirapine associated with ZDV/3TC (the COMBINE-QoL substudy)
    A Casado
    University of Barcelona, Barcelona, Spain
    HIV Clin Trials 5:132-9. 2004
    ..The aim of the study was to assess differences in health-related quality of life (HRQoL) in HIV-infected naive patients treated with two HAART regimens at 12 months...
  12. ncbi Highly active antiretroviral treatment (HAART) and health-related quality of life in naive and pretreated HIV-infected patients
    A Casado
    Unitat de Recerca en Resultats Sanitaris, Departament d Epidemiología Clínica y Salut Pública, Hospital de la Santa Creu y Sant Pau, Barcelona, Spain
    HIV Clin Trials 2:477-83. 2001
    ....
  13. ncbi Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy
    Xavier Badia
    Department of Clinical Epidemiology and Public Health, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Antivir Ther 9:979-85. 2004
    ..To evaluate health-related quality of life (HRQoL) changes in patients treated with indinavir three-times daily after switching to a twice-daily indinavir/ritonavir regimen or continuing with the same regimen...
  14. doi Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study
    Josep Mallolas
    Hospital Clinic Universitari IDIBAPS, University of Barcelona, Barcelona, Spain
    J Acquir Immune Defic Syndr 51:29-36. 2009
    ..To evaluate the efficacy and safety of switching from boosted lopinavir (LPV/r) to boosted atazanavir (ATV/r) in virologically suppressed HIV-1-infected patients versus continuing LPV/r...
  15. ncbi Long-term benefits of nevirapine-containing regimens: multicenter study with 506 patients, followed-up a median of 9 years
    D Podzamczer
    HIV Unit, Infectious Disease Service, Hospital Universitari de Bellvitge, c Feixa Llarga s n L Hospitalet de Llobregat, 08907 Barcelona, Spain
    Curr HIV Res 10:513-20. 2012
    ..To evaluate long-term outcomes in patients maintaining a nevirapine (NVP)-based regimen...
  16. doi HIV-1 infected patients older than 50 years. PISCIS cohort study
    G Navarro
    Corporación Sanitaria Parc Taulí, Sabadell, Barcelona, Spain
    J Infect 57:64-71. 2008
    ..The aim of this study is to characterize the ways in which older HIV-infected people differ from younger HIV-infected people...
  17. ncbi Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group
    J M Gatell
    Hospital Clinic, Barcelona, Spain
    J Acquir Immune Defic Syndr Hum Retrovirol 12:249-58. 1996
    ..This effect tended to be greater among individuals with higher CD4 counts (>100/mm3)...
  18. doi Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz T
    Jose M Miro
    Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    AIDS Res Hum Retroviruses 26:747-57. 2010
    ..At 1 and 3 years, the immune reconstitution induced by an efavirenz-based regimen in very immunosuppressed patients was at least as potent as that induced by a ritonavir-boosted protease inhibitor-based antiretroviral regimen...
  19. doi Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort
    C Manzardo
    Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    Clin Microbiol Infect 19:646-53. 2013
    ..002; hazard ratio 1.83; 95% CI 1.25-2.68). Other independent risk factors for poorer outcome were baseline diagnosis of AIDS-defining lymphoma, age >35 years, and low CD4(+) count (<50 cells/μL)...
  20. doi Impact of antiretroviral therapy interruption on plasma biomarkers of cardiovascular risk and lipids: 144-week final data from the STOPAR study
    M Olmo
    Infectious Disease Service, Bellvitge University Hospital, Bellvitge Biomedical Research Institute IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
    HIV Med 13:488-98. 2012
    ..The aim of the study was to investigate changes in plasma biomarkers of cardiovascular risk and lipids in a CD4-guided antiretroviral therapy interruption study...
  21. ncbi Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine
    Montserrat Plana
    Institut Clinic d Infeccions i Immunologia, Immunology, Infectious Diseases and Microbiology Units, Institut de Investigació Biomèdica Agusti Pi i Suñer, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Antivir Ther 9:197-204. 2004
    ..To evaluate the immunological response in HIV-1-infected, antiretroviral-naive patients receiving highly active antiretroviral therapy regimen of two nucleosides plus a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor...
  22. ncbi Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients
    Esteban Martinez
    Hospital Clinic, Barcelona, Spain
    AIDS 21:367-9. 2007
    ..In contrast, abacavir showed a lower incidence of adverse effects leading to drug discontinuation...
  23. doi Etravirine concentrations in seminal plasma in HIV-infected patients
    J M Tiraboschi
    HIV Unit, Infectious Disease Service, Hospital Universitari de Bellvitge, L Hospitalet de Llobregat, 08907 Barcelona, Spain
    J Antimicrob Chemother 68:184-7. 2013
    ..To determine etravirine concentrations and the HIV-1 viral load (VL) in blood plasma (BP) and seminal plasma (SP) of HIV-infected patients...
  24. ncbi Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality
    Miriam J Alvarez-Martinez
    Hospital Clinic IDIBAPS, Universitat de Barcelona, Barcelona, Spain
    Diagn Microbiol Infect Dis 62:34-43. 2008
    ..03 and P < 0.001, respectively). The prevalence of DHPS mutants in Spain is low and is not associated with a worse outcome. Severe respiratory failure at admission is the strongest predictor of PCP outcome...
  25. doi Progression to AIDS or death in HIV-infected patients initiating cART with CD4<200 cells/µL: the role of CD4 and viral load changes during follow-up
    E Ferrer
    Hospital Universitari de Bellvitge, HIV Unit, Infectious Disease Service, Barcelona, Spain
    J Int AIDS Soc 15:18148. 2012
    ..VL at BL and mainly at follow up also played a role in patient outcome...
  26. doi Etravirine concentrations in seminal plasma in HIV-infected patients
    J Tiraboschi
    Hospital Universitari de Bellvitge, HIV Unit, Barcelona, Spain
    J Int AIDS Soc 15:18341. 2012
    ..Conclusions: Total etravirine concentrations in male genital secretion are modest, reaching only 16% of the BP concentration, but nevertheless, more than 10 times above the wild type IC50 range...
  27. ncbi Impact of hepatitis C virus coinfection on immune restoration during successful antiretroviral therapy in chronic human immunodeficiency virus type 1 disease
    M Santin
    Department of Infectious Diseases, IDIBELL, Hospital Universitari de Bellvitge, University of Barcelona, c Feixa Llarga s n, 08907, L Hospitalet, Barcelona, Spain
    Eur J Clin Microbiol Infect Dis 27:65-73. 2008
    ..However, as good control of viral replication is maintained, satisfactory long-term immune restoration can nonetheless be achieved...
  28. doi Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study)
    M Saumoy
    Infectious Disease Service, Bellvitge University Hospital, Sant Pau Hospital and Autonomous University, Barcelona, Spain
    HIV Med 12:438-41. 2011
    ..The aim of the study was to evaluate the efficacy of fosamprenavir/ritonavir (FPV/r) monotherapy in plasma and reservoirs in virologically suppressed patients...
  29. ncbi Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir
    E Martinez
    Hospital Clinic IDIBAPS, Universitat de Barcelona, Barcelona, Spain
    HIV Med 15:330-8. 2014
    ....
  30. doi Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicenter cohort of HIV-infected ARV-experienced patients
    D Podzamczer
    Hospital Univeristari de Bellvitge, Barcelona, Spain
    J Int AIDS Soc 15:18343. 2012
    ..A favourable lipid profile was observed after 96 weeks of follow up...
  31. doi Objective amount of limb fat in HIV-infected subjects with subjective diagnosis of lipoatrophy
    E Martinez
    Infectious Diseases Unit, Hospital Clinic Institut d Investigaciones Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    HIV Med 10:257-61. 2009
    ..The relationship between the subjective diagnosis of lipoatrophy and the objective amount of limb fat loss in HIV-infected adults is unclear...
  32. ncbi New patterns of HIV-1 resistance during HAART
    E Fumero
    Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain
    Clin Microbiol Infect 9:1077-84. 2003
    ..Resistance to the new entry inhibitor class compound T-20 (enfuvirtide) has also been detected...
  33. ncbi Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/microl or less
    Elena Ferrer
    Infectious Disease Services, Universitari de Bellvitge Hospital, Barcelona, Spain
    AIDS 18:1727-9. 2004
    ..More than 80% of patients who continued with nevirapine had viral loads < 50 copies/ml and CD4 cell counts > 200 cells/pl...
  34. doi Etravirine concentrations in CSF in HIV-infected patients
    J M Tiraboschi
    HIV Unit, Infectious Disease Service, Hospital Universitari de Bellvitge, L Hospitalet de Llobregat, 08907 Barcelona, Barcelona, Spain
    J Antimicrob Chemother 67:1446-8. 2012
    ..To determine etravirine concentrations in CSF in HIV-infected patients...
  35. doi Trends in mortality and antibiotic resistance among HIV-infected patients with invasive pneumococcal disease
    I Grau
    Infectious Disease Service, IDIBELL, CibeRes, Hospital Bellvitge, University of Barcelona, Barcelona, Spain
    HIV Med 10:488-95. 2009
    ..The aim of the study was to describe trends and risk factors for mortality and changes in antibiotic resistance, serotypes and clones among HIV-infected patients with invasive pneumococcal disease (IPD)...
  36. ncbi A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study
    Cesar Fisac
    Endocrinology Services, Hospital Universitario de Bellvitge, 08907 L Hospitalet de Llobregat, Barcelona, Spain
    J Clin Endocrinol Metab 88:5186-92. 2003
    ..Inclusion of NVP should be considered when deciding upon antiretroviral regimens for patients at high coronary risk...
  37. doi Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression
    Jose R Santos
    Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain
    HIV Clin Trials 10:432-8. 2009
    ..To assess the Efficacy and safety of switching from HAART containing enfuvirtide to raltegravir as a simplification strategy in patients with viral suppression and intolerance to enfuvirtide...
  38. ncbi Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine
    Cesar Fisac
    Nutrition Section, Hospital Universitari de Bellvitge, L Hospitalet de Llobregat, Barcelona, Spain
    AIDS 19:917-25. 2005
    ..To evaluate the 24-month metabolic and morphological benefits obtained from replacing the protease inhibitor (PI) in a regimen with nevirapine, efavirenz or abacavir...
  39. ncbi A review of nelfinavir for the treatment of HIV infection
    Montserrat Olmo
    Hospital Universitario de Bellvitge, Infectious Diseases Service, HIV Unit, Hospitalet de Llobregat, Barcelona, Spain
    Expert Opin Drug Metab Toxicol 2:285-300. 2006
    ..In addition, its new simplified posology may contribute to improved adherence...
  40. ncbi Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment
    Patricia Barragan
    Hospital Universitari de Bellvitge, Feixa Llarga s n L Hospitalet de Llobregat, 08907, Barcelona, Spain
    Expert Opin Pharmacother 9:2363-75. 2008
    ..Numerous clinical trials have shown that lopinavir/ritonavir (LPV/r) is highly effective as a component of highly active antiretroviral therapy (HAART) regimens for HIV-1 infection...
  41. doi Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study
    Elena Ferrer
    Infectious Disease and Hospital Universitari de Bellvitge, L Hospitalet, Barcelona, Spain
    AIDS Res Hum Retroviruses 24:931-4. 2008
    ..Larger trials comparing this option with standard initial antiretroviral regimens should be conducted...
  42. doi Effectiveness of first-line antiretroviral therapy based on NNRTIs vs ritonavir-boosted PIs in HIV-1 infected patients with high plasma viral load
    A Imaz
    Hospital Universitari de Bellvitge, Department of Infectious Diseases, Barcelona, Spain
    J Int AIDS Soc 15:18235. 2012
    ..Resistance emergence was more frequent and pVL higher in patients failing NNRTI. However, more patients initiating PI/r-based regimens changed or discontinued therapy...
  43. ncbi Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study
    Vicenc Falco
    Infectious Disease Department, Hospital Universitario Vall d Hebron, Barcelona, Spain
    J Acquir Immune Defic Syndr 49:26-31. 2008
    ....
  44. ncbi [Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project]
    Angeles Jaén
    Centre d Estudis Epidemiològics sobre la SIDA de Catalunya CEESCAT, DGSP, Departament de Salut, Badalona, Barcelona, Spain
    Med Clin (Barc) 124:525-31. 2005
    ....
  45. ncbi Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy
    Imma Grau
    Infectious Disease Service, Clinical Research Unit, IDIBELL Hospital de Bellvitge and University of Barcelona, Barcelona, Spain
    Arch Intern Med 165:1533-40. 2005
    ..The use of highly active antiretroviral therapy (HAART) may change the incidence of, and the risk and prognostic factors for, invasive pneumococcal disease in patients with human immunodeficiency virus (HIV)...
  46. ncbi Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial
    Jose M Miro
    Institut d Investigacions Biomediques August Pi Sunyer Hospital Clinic, University of Barcelona, Barcelona, Spain
    Clin Infect Dis 43:79-89. 2006
    ..To our knowledge, no randomized trials have evaluated whether prophylaxis against toxoplasmic encephalitis can be safely discontinued after the CD4+ T cell count increases in response to highly active antiretroviral therapy...
  47. pmc Incidence and molecular typing of Mycobacterium kansasii in a defined geographical area in Catalonia, Spain
    M Santin
    Department of Infectious Diseases, Hospital Universitari de Bellvitge, Barcelona, Spain
    Epidemiol Infect 132:425-32. 2004
    ..kansasii disease in our area. M. kansasii disease in our geographical area was almost exclusively caused by subtype I regardless of HIV status...
  48. pmc Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient
    Patricia Barragan
    Infectious Disease Service, Hospital Universitari de Bellvitge, L Hospitalet, Barcelona, Spain
    Am J Trop Med Hyg 83:10-2. 2010
    ..We report the case of a human immunodeficiency virus-1-infected patient who had several relapses of visceral leishmaniasis after treatment with standard therapies and responded to a combined therapy...
  49. ncbi [Recommendations of GESIDA/Spanish National Plan of AIDS on diagnosis and treatment of Kaposi's sarcoma and cervical cancer in HIV-infected patients]
    Daniel Podzamczer
    Ciutat Sanitaria de Bellvitge, L Hospitalet, Barcelona, Spain
    Med Clin (Barc) 118:788-95. 2002
  50. ncbi Switching strategies to improve lipid profile and morphologic changes
    Patricia Barragan
    Infectious Disease Service, Hospital Universitari de Bellvitge, L Hospitalet, Barcelona, Spain
    AIDS Rev 8:191-203. 2006
    ..In this setting, switching strategies may be useful to minimize clinical and psychological consequences, improving the quality of life of HIV-infected patients treated with HAART...
  51. ncbi Community associated methicillin-resistant Staphylococcus aureus in HIV-infected patients
    Arkaitz Imaz
    HIV Unit, Infectious Diseases Service, Hospital Universitari de Bellvitge, Barcelona, Spain
    AIDS Rev 12:153-63. 2010
    ..This article summarizes the current knowledge regarding associated risk factors, clinical manifestations, and management of community-acquired methicillin-resistant Staphylococcus aureus infections in HIV-infected patients...
  52. ncbi Considerations on the increase in blood pressure among antiretroviral-naive patients starting HAART
    Esteban Martinez
    AIDS 21:384-6. 2007
  53. ncbi Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    N Engl J Med 349:1036-46. 2003
    ..We assessed the strategy of substituting nevirapine, efavirenz, or abacavir for a protease inhibitor in patients infected with human immunodeficiency virus type 1 (HIV-1) in whom virologic suppression had been achieved...
  54. ncbi Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma
    Luz Martin-Carbonero
    AIDS 18:1737-40. 2004
    ..After 48 weeks, better response rates were observed in the HAART plus PLD group (76% versus 20%). In HIV-infected patients with moderate-advanced KS, HAART alone may not be enough for KS response...
  55. ncbi Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain)
    Angeles Jaén
    Centre d Estudis Epidemiològics sobre ITS VIH SIDA de Catalunya, Badolona, Spain CEEISCAT, Coordinating Center
    J Acquir Immune Defic Syndr 47:212-20. 2008
    ....
  56. ncbi [Validation of a questionnaire to estimate satisfaction with antiretroviral treatment: CESTA questionnaire]
    Emilia Condes
    Servicio de Medicina Interna, Hospital de Mostoles, Madrid, Spain
    Enferm Infecc Microbiol Clin 23:586-92. 2005
    ..Currently, there is no validated patient satisfaction questionnaire to evaluate this factor as related to control of the disease...
  57. ncbi Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load
    Juan A Arnaiz
    Hospital Clinic IDIBAPS, University of Barcelona, Spain
    AIDS 17:831-40. 2003
    ....
  58. ncbi Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort
    Juan Berenguer
    Infectious Diseases and HIV Unit, Hospital Gregorio Maranon, Madrid, Spain
    J Acquir Immune Defic Syndr 41:154-9. 2006
    ..To analyze the safety and effectiveness of abacavir, lamivudine, and zidovudine (ABC/3TC/ZDV) in antiretroviral therapy (ART)-naive HIV-infected patients...
  59. ncbi Genotypic resistance in HIV-infected naive patients receiving abacavir plus lamivudine and efavirenz
    Elena Ferrer
    J Acquir Immune Defic Syndr 46:253-5. 2007
  60. ncbi [Spanish cohort of naïve HIV-infected patients (CoRIS): rationale, organization and initial results]
    Ana María Caro-Murillo
    Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain
    Enferm Infecc Microbiol Clin 25:23-31. 2007
    ..To describe the methodology and baseline results of the Spanish cohort of naïve HIV-infected patients included in the Research Network on HIV/AIDS (CoRIS)...
  61. ncbi A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen
    Margaret A Johnson
    Royal Free Center for HIV Medicine, London, United Kingdom
    J Acquir Immune Defic Syndr 43:153-60. 2006
    ..To evaluate the safety and noninferiority and to explore the efficacy of administration of once-daily versus twice-daily lopinavir/ritonavir (LPV/r) in antiretroviral-naive HIV-1-infected subjects...
  62. doi Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin
    L Martin-Carbonero
    Dept of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 47:410-7. 2008
    ..However, this tumor still represents the most common cancer in this population...
  63. ncbi Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations
    Marina Nunez
    Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
    Med Sci Monit 8:CR620-3. 2002
    ..The purpose of our study was to assess the presence of nelfinavir (NFV)-associated resistance mutations at the time of early virological failure in subjects receiving NFV as part of a first protease inhibitor (PI)-based triple regimen...